Analysts have clear opinions on AMED.
There are 9 analysts on the Wall offering 12 month price targets for Amedisys in the last 3 months. The average price target is $165.75 with a high forecast of $200.00 and a low forecast of $134.00. The average price target represents a -6.20% decrease from the last price of $176.71.
Amedisys, Inc. (AMED) is followed by 9 analysts on the street.
John Ransom from Raymond James rates it a Buy with a target of $200.00.
Similarly, Last month David S Macdonald of SunTrust Robinson Reiterated a Buy with a target of $185.00.
The consensus on the street is Moderate Buy.
What does Amedisys, Inc.(AMED) do ?
Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.
Amedisys, Inc. (AMED) Insider Trades
Multiple company employees have indulged in significant insider trading. Amedisys, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):
Dir, Klapstein Julie D : S – Sale(-$41,073) of AMED in the trading session of 2020-01-02.
COO Gerard Christopher : S – Sale(-$57,829) of AMED in the trading session of 2020-01-02.
Dir Rideout Jeffrey A : S – Sale(-$96,648) of Amedisys, Inc. in the trading session of 2019-12-13.
Looking for stocks just like AMED?
Based on Wall Street analyst research, several stocks are similar to AMED
– LHCG [Info can be found here: https://www.nasdaq.com/market-activity/stocks/LHCG ]
– CHE [Info can be found here: https://www.nasdaq.com/market-activity/stocks/CHE ]